Condition: Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy · Sponsor: SANGMYUNG innovation
The purpose of this study is to evaluate the efficacy and safety of SMZ1 tablets in combination with Ranibizumab compared with placebo in combination with Ranibizumab in subjects with neovascular (wet) age-related macular degeneration (nAMD) without polypoidal choroidal vasculopathy (PCV). The primary objective is to demonstrate the superiority of SMZ1 tablets over placebo with respect to improvement in best-corrected visual acuity at Month 12.
This description comes directly from the study's public registry record.
Nahyun Kang, Ph.D · +82 2-3489-6298 · nahyun.kang@sminnovation.com
Always discuss trial participation with your own doctor first.
| Kyung Hee University Hospital | Seoul, Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07695207